Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teramed Targets Contraindicated Patients For AAA Stent Graft Market Entry

This article was originally published in The Gray Sheet

Executive Summary

Teramed's kick-off of clinical studies for the Ariba and Tributary abdominal aortic aneurysm stent graft systems indicates both the rapid pace of differentiating innovation in the AAA market and industry's continued interest in minimally invasive surgical solutions to vascular disease.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel